Nuvation Bio Inc
NUVB2.265USD
+0.035+1.57%
交易中 （美东）报价延迟15分钟
769.74M总市值
亏损市盈率 TTM
关于 Nuvation Bio Inc 公司
Nuvation Bio Inc. 是一家生物制药公司。该公司致力于通过开发差异化和治疗候选药物来解决肿瘤学中未满足的需求。该公司正在推进多个临床阶段候选药物，包括 ROS1 抑制剂、突变异柠檬酸脱氢酶 1 (mIDH1) 抑制剂、溴结构域和额外末端 (BET) 抑制剂以及药物-药物偶联物 (DDC)。其开发候选药物组合包括塔雷替尼 (ROS1)、沙夫西地尼 (mIDH1)、NUV-868 (BET) 和 NUV-1511 (DDC)。塔雷替尼是一种口服、强效、中枢神经系统活性、选择性 ROS1 抑制剂，专为治疗 ROS1 阳性非小细胞肺癌 (NSCLC) 而设计。 Safusidenib 是一种口服的强效靶向 mIDH1 抑制剂，目前正在全球 II 期试验中对低级别 IDH1 突变型胶质瘤患者进行评估。NUV-868 是一种 BD2 选择性口服小分子 BET 抑制剂，可抑制 BRD4。该公司正在对 NUV-1511 进行 I/II 期研究。
公司简介
公司代码NUVB
公司名称Nuvation Bio Inc
上市日期Jul 01, 2020
CEODr. David T. Hung, M.D.
员工数量220
证券类型Ordinary Share
年结日Jul 01
公司地址357 Tehama Street, Floor 3
城市SAN FRANCISCO
上市交易所NYSE Consolidated
国家United States of America
邮编94103
电话14157543517
网址https://www.nuvationbio.com/
公司代码NUVB
上市日期Jul 01, 2020
CEODr. David T. Hung, M.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. David T. Hung, M.D.
Dr. David T. Hung, M.D.
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
60.28M
+0.84%
Mr. Kim D. Blickenstaff
Mr. Kim D. Blickenstaff
Independent Director
Independent Director
172.19K
--
Dr. Robert Mashal, M.D.
Dr. Robert Mashal, M.D.
Independent Director
Independent Director
100.00K
--
Ms. Colleen Sjogren
Ms. Colleen Sjogren
Chief Commercial Officer
Chief Commercial Officer
78.00K
+178.57%
Ms. Kerry A. Wentworth
Ms. Kerry A. Wentworth
Chief Regulatory Officer
Chief Regulatory Officer
50.00K
--
Mr. Moses Makunje, CPA
Mr. Moses Makunje, CPA
Principal Accounting Officer, Vice President - Finance
Principal Accounting Officer, Vice President - Finance
10.61K
--
Ms. Stacy Markel
Ms. Stacy Markel
Chief People Officer
Chief People Officer
10.00K
--
Mr. Philippe Sauvage
Mr. Philippe Sauvage
Chief Financial Officer and Principal Financial Officer
Chief Financial Officer and Principal Financial Officer
7.30K
--
Mr. Robert B. (Rob) Bazemore, Jr.
Mr. Robert B. (Rob) Bazemore, Jr.
Lead Independent Director
Lead Independent Director
5.00K
--
Mr. Joe Rayne
Mr. Joe Rayne
Investor Relations
Investor Relations
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. David T. Hung, M.D.
Dr. David T. Hung, M.D.
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
60.28M
+0.84%
Mr. Kim D. Blickenstaff
Mr. Kim D. Blickenstaff
Independent Director
Independent Director
172.19K
--
Dr. Robert Mashal, M.D.
Dr. Robert Mashal, M.D.
Independent Director
Independent Director
100.00K
--
Ms. Colleen Sjogren
Ms. Colleen Sjogren
Chief Commercial Officer
Chief Commercial Officer
78.00K
+178.57%
Ms. Kerry A. Wentworth
Ms. Kerry A. Wentworth
Chief Regulatory Officer
Chief Regulatory Officer
50.00K
--
Mr. Moses Makunje, CPA
Mr. Moses Makunje, CPA
Principal Accounting Officer, Vice President - Finance
Principal Accounting Officer, Vice President - Finance
10.61K
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 5月16日 周五
更新时间: 5月16日 周五
持股股东
股东类型
持股股东
持股股东
占比
Hung (David T)
17.72%
Fidelity Management & Research Company LLC
14.70%
Decheng Capital LLC
7.63%
BlackRock Institutional Trust Company, N.A.
4.66%
The Vanguard Group, Inc.
4.51%
Other
50.78%
持股股东
持股股东
占比
Hung (David T)
17.72%
Fidelity Management & Research Company LLC
14.70%
Decheng Capital LLC
7.63%
BlackRock Institutional Trust Company, N.A.
4.66%
The Vanguard Group, Inc.
4.51%
Other
50.78%
股东类型
持股股东
占比
Investment Advisor
30.97%
Individual Investor
19.30%
Hedge Fund
12.40%
Investment Advisor/Hedge Fund
9.48%
Venture Capital
8.02%
Research Firm
1.03%
Bank and Trust
0.20%
Pension Fund
0.17%
Private Equity
0.01%
Other
18.42%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
340
277.65M
81.60%
-29.03M
2025Q1
346
276.31M
81.30%
-31.14M
2024Q4
336
290.52M
86.58%
+4.56M
2024Q3
324
278.55M
83.07%
+36.83M
2024Q2
323
221.78M
89.68%
-2.09M
2024Q1
305
194.38M
89.06%
-41.04M
2023Q4
290
194.02M
89.00%
-35.90M
2023Q3
285
196.95M
90.37%
-25.21M
2023Q2
286
199.03M
91.34%
-20.86M
2023Q1
290
197.27M
90.57%
-23.29M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Hung (David T)
60.28M
17.72%
+500.00K
+0.84%
Jun 16, 2025
Fidelity Management & Research Company LLC
50.03M
14.7%
+5.31M
+11.88%
Mar 31, 2025
Decheng Capital LLC
25.95M
7.63%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
15.87M
4.66%
-60.61K
-0.38%
Mar 31, 2025
The Vanguard Group, Inc.
15.34M
4.51%
-334.75K
-2.14%
Mar 31, 2025
Omega Fund Management, LLC
13.07M
3.84%
--
--
Mar 31, 2025
Laurion Capital Management LP
9.87M
2.9%
+3.38M
+52.06%
Mar 31, 2025
Octagon Capital Advisors LP
7.90M
2.32%
-1.30M
-14.16%
Mar 31, 2025
Geode Capital Management, L.L.C.
5.13M
1.51%
+179.41K
+3.62%
Mar 31, 2025
State Street Global Advisors (US)
4.86M
1.43%
+256.02K
+5.57%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
Virtus LifeSci Biotech Clinical Trials ETF
0.97%
SPDR S&P Pharmaceuticals ETF
0.89%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
0.63%
ALPS Medical Breakthroughs ETF
0.45%
iShares U.S. Pharmaceuticals ETF
0.25%
iShares Micro-Cap ETF
0.11%
iShares Health Innovation Active ETF
0.08%
Avantis US Small Cap Equity ETF
0.06%
iShares Biotechnology ETF
0.05%
Fidelity Enhanced Small Cap ETF
0.04%
查看更多
Virtus LifeSci Biotech Clinical Trials ETF
占比0.97%
SPDR S&P Pharmaceuticals ETF
占比0.89%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
占比0.63%
ALPS Medical Breakthroughs ETF
占比0.45%
iShares U.S. Pharmaceuticals ETF
占比0.25%
iShares Micro-Cap ETF
占比0.11%
iShares Health Innovation Active ETF
占比0.08%
Avantis US Small Cap Equity ETF
占比0.06%
iShares Biotechnology ETF
占比0.05%
Fidelity Enhanced Small Cap ETF
占比0.04%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
